Co-Diagnostics (CODX) Reports In-Line Q3 EPS

Co-Diagnostics (NASDAQ: CODX) reported Q3 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings